# US 2012/0252769 A1 · 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252769 A1
- Document ID: US20120252769A1
- Status: Published application
- Kind: A1
- Application number: 13/246,441
- Filed: 2011-09-27
- Published: 2012-10-04
- Earliest claimed: 1998-05-15
- Assignees: Wyeth
- Inventors: James Harrison PICKAR; Barry Samuel KOMM
- Web page: https://patentgrep.com/patent/US20120252769A1

## CPC

- A61K 31/566: having an oxo group in position 17, e.g. estrone
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61P 5/30: Oestrogens
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:

## Claims

### Claim 1

A pharmaceutical composition comprising an oral dosage comprising a tablet or capsule for the treatment of post-menopausal syndrome comprising conjugated estrogens, in the amount of 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg or 1.25 mg, and 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof, in the amount of from about 1 mg to about 150 mg, and a pharmaceutically acceptable carrier or excipient.
